Dr. John Leonard

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

The sixth annual Symposium on Entrepreneurship and Academic Drug Development, hosted Nov. 14, showcased Weill Cornell’s rich array of programs for supporting faculty who want to bring their discoveries to the health care marketplace.

Dr. Sheila Nirenberg, the Nanette Laitman Professor of Neurology and Neuroscience and a professor of physiology and biophysics at Weill Cornell Medicine, has received the Barbara McClintock Women Innovator Award at the Inaugural Women Innovator Awards.

The fifth annual symposium spotlighted an expanding list of entrepreneurial translation efforts at the institution.

Weill Cornell Medicine has received complementary grants from Genentech and the Leukemia & Lymphoma Society (LLS) to support a new program that aims to address socioeconomic and racial disparities and increase access to clinical trials for underserved patients with blood cancers living in Brooklyn and Queens.

The environment surrounding the cancerous cells of a lymphoma tumor has a strong influence on the progression of these blood-cell cancers and their responses to therapies.

Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.

Dr. John Leonard, an esteemed physician-scientist who specializes in lymphoma research and treatment, has been named senior associate dean for innovation and initiatives at Weill Cornell Medicine. 

Awards, honors, prizes and achievements for the month of May.

The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time. 

Awards, honors, prizes and achievements for the month of March.

Newer, non-chemotherapy drugs benefit many patients with mantle cell lymphoma, an incurable form of blood cancer, and deserve deeper study in clinical trials, according to an editorial published Sept. 12 in Blood by scientists at Weill Cornell Medicine and NewYork-Presbyterian.

Dr. Robert Burakoff has been named vice chair for ambulatory services for the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and site chief for the Division of Gastroenterology and Hepatology at NewYork-Presbyterian Lower Manhattan Hospital and Weill Cornell Medicine.

For decades, Weill Cornell has been a leader in the research revolution that's making lymphoma a survivable disease.

Social media extolled for its power to amplify scientific messages at inaugural Social Media Summit.